Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
January 10, 2018
Date of Report (Date of earliest event reported)
Chimerix, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Commission File Number)
(IRS Employer Identification No.)
of incorporation)
2505 Meridian Parkway, Suite 100
Durham, NC
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (919) 806-1074
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.
Attached hereto as Exhibit 99.1 and incorporated herein by reference is a corporate update presentation to be utilized by Chimerix, Inc. at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

The information in this Item 7.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Forward-Looking Statements

Statements contained in, or incorporated by reference into, this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in our filings with the Securities and Exchange Commission, including without limitation our most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Item 9.01
Financial Statements and Exhibits.
Exhibit No.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Chimerix, Inc.
Dated: January 10, 2018
/s/ Timothy W. Trost
Timothy W. Trost
Senior Vice President, Chief Financial Officer and Corporate Secretary


2 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that there may not be a viable continued development path for brincidofovir, that any clinical trials we may conduct will not demonstrate adequate efficacy and safety of brincidofovir, that the FDA and other regulatory authorities may not approve brincidofovir or brincidofovir-based regimens, and that marketing approvals, if granted, may have significant limitations on their use. As a result, brincidofovir may never be successfully commercialized. In addition, Chimerix may be unable to file for regulatory approval for brincidofovir with other regulatory authorities. Similar risks and uncertainties apply to our development of CMX521. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Chimerix's Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 and other documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Chimerix, and Chimerix assumes no obligation to update any such forward-looking statements.

3 Why Are We Excited About 2018?  AdAPT trial of short-course oral BCV for adenovirus enrolling and data expected in 2019; if positive, data should support first regulatory approval  Lack of GI side-effects with multiple doses of IV BCV supports progression to Phase 2 patient studies in 2018, leading to potential studies in prevention and treatment of multiple viruses including AdV, CMV, and BKV in 2019  Regulatory submissions for marketing approval of oral BCV for smallpox are planned for 2019  CMX521, the first direct-acting antiviral specific for norovirus, is now in clinical stage development  We have patent protection through 2034 and sufficient capital to progress oral BCV to value-generating data and/or procurement contracts

4 Data-Rich 2018 and 2019 Ahead of Regulatory Decisions Oral BCV Adenovirus  Enrolling AdAPT  AdVance Data  Enrolling AdAPT Adult AdAPT Data Smallpox  Pivotal mouse study  Pivotal mouse study  Supportive rabbit study  MAA submission  NDA submission IV BCV Adenovirus and CMV  Initiate Phase 2 in patients  Phase 2 in patients  Initiate MVP pivotal trial Compound Indication 1H 2018 2H 2018 2019 CMX521 Treatment of Chronic Norovirus  Ph 1 single dose study  Ph 1 multiple dose study  Norovirus: Challenge / Proof-of-Concept trial Prevention of Norovirus Outbreaks

5 CMRX: Developing Solutions for Immunocompromised Patients  Experienced and committed management team with successful track records developing significant antiviral drugs and first-in-indication commercial launches  Lead compound brincidofovir has broad-spectrum antiviral activity – Short-course oral BCV in late-stage development for treatment of smallpox and adenovirus – New IV BCV formulation for prevention of serious viral infections in transplant recipients and treatment of viral diseases in the growing immunocompromised patient population  Proprietary lipid-conjugate technology has led to two clinical-stage compounds – Brincidofovir (CMX001, BCV) and CMX157, licensed to ContraVir  CMX521: newest investigational compound for norovirus – Developed from Chimerix Chemical Library – First clinical dosing began in December 2017

6 Brincidofovir: Broad Spectrum Antiviral For dsDNA Viruses Viral Family Virus BCV Cidofovir Maribavir Letermovir Ganciclovir* Foscarnet Acyclovir Herpes Cytomegalovirus 0.001 0.4 0.31 0.005 3.8 50-800 >200 Epstein-Barr Virus 0.03 65.6 0.63 >10 0.9 <500 6.2 Human Herpesvirus 6 0.003 2.7 Inactive >10 5.8 16 10 Human Herpesvirus 8 0.02 2.6 Inactive ― 8.9 177 >100 Herpes Simplex Virus 1 0.01 3.0 Inactive >10 0.7 92-95 3.8 Herpes Simplex Virus 2 0.02 6.5 Inactive >10 2.5 91-96 4.4 Varicella Zoster Virus 0.0004 0.5 Inactive >10 1.3 39.8 3.6 Adenovirus Adenovirus (AdV-B7) 0.02 1.3 ― >10 4.5-33 Inactive >100 Polyoma BK Virus (BKV) 0.13 115 ― ― >200 Inactive >200 JC Virus (JCV) 0.045 >0.1 ― ― ― Inactive ― Papilloma Human Papillomavirus 17 716 ― ― Inactive ― Inactive Pox Variola 0.1 27 ― ― ― ― ― Vaccinia 0.8 46 ― ― >392 Inactive >144 Potency expressed as EC50 = concentration in µM required to reduce viral replication by 50% in vitro; “―” indicates no data. *Valganciclovir is rapidly converted to ganciclovir in vivo; ganciclovir is the relevant compound for cell activity studies. Source: Data are compiled from multiple sources and include multiple materials and methodologies.

7 AdAPT Now Enrolling – Data Expected in 2019 2017 2018 2019 2020 AdAPT DATA Oral BCV for AdV All timelines are estimated AdAPT Adult  Study being conducted in US, UK and EU  Short-course oral treatment for acute life-threatening adenovirus infections – Potent antiviral with high barrier to resistance – Rapid reduction of AdV viral load in blood and other compartments – Short-course treatment minimizes risk of side effects

Follow up Period Potential Treatment Period Potential Treatment Period 8 AdAPT: Adenovirus after Allogeneic Pediatric Transplantation  Open label, comparative study of oral BCV vs. standard of care (SoC) in AdV viremia – Pediatric T-cell depleted allo-HCT recipients during first 100 days of HCT  Short-course therapy: “Treat-to-clear” paradigm – BCV or SoC administered until AdV is cleared from plasma  Primary endpoint: AdV viral burden over 16 weeks – Agreed by CHMP and FDA  Study size: N=141 to be randomized 2:1 to oral BCV or local standard of care Oral BCV BIW Standard of Care n=94 16 8 Week 0 4 12 n=47 24 36 Follow up Period

9 Maximizing the Probability of Success for AdAPT  Study design incorporates key learnings for oral brincidofovir: – Includes highest risk patients: pediatric recipients of T-cell depleted HCT prior to immune reconstitution – Short-course oral BCV therapy begun within the first three weeks of adenoviremia • Rapidly clears virus • Minimizes side effects – Primary endpoint is AdV burden over time, the most sensitive measure to differentiate the antiviral effect of oral BCV from SoC – >90% power to show superiority of brincidofovir to local SoC – Open-label study – randomized but not blinded  Study sites are experienced with BCV, prospectively monitor for AdV and have expertise in treating AdV infections in high-risk patient populations

Rapid Antiviral Effect of Oral Brincidofovir vs Local SOC* Oral BCV from AdVise 3 yr old pt 41 days post-TCD HCT Local Standard of Care (SoC) from AdVance 2 yr old pt 19 days post-HCT 21 mo, Campath, 19d post HCT 4 2 8 12 0 16 WEEK -4 0 -4 4 2 8 12 16 WEEK  Detection of AdV in the blood after transplant predicts rapid progression to AdV disease and death in high-risk transplant recipients  Oral BCV has demonstrated rapid clearance of AdV viremia  BCV does not require immune reconstitution to provide viral load reductions Average Viral Load = 4.40 log10 copies/mL † Average Viral Load = 2.03 log10 copies/mL † *Local standard-of-care may include reduction of immunosuppressants or off-label IV cidofovir † Lower limit of detection: 2 log copied/mL 10

11 Regulatory Acceptance of AdV Viral Load as a Surrogate Endpoint for Pivotal Studies  AdAPT was designed with European regulators; positive data should support full or conditional approval  FDA has recently announced CMV viremia as an acceptable surrogate endpoint for pivotal CMV studies; viremia without statistically significant mortality sets an important precedent for anticipated discussions on results from AdAPT  We are working with international experts to build similar substantial evidence in support of AdV viral load as an acceptable surrogate endpoint for pivotal studies – European Group for Blood and Marrow Transplant (EBMT) plans to publish ID Working Group position paper with state-of-the-art screening and treatment recommendations for the diagnosis and treatment of adenovirus after HCT – AdVance: multiple abstracts planned for EBMT March 2018 that demonstrate the correlation of AdV viral burden with risk of mortality – Multiple independent analyses from transplant centers across Europe and the US show a strong correlation of AdV viral load, disease and mortality

Early development work shows great promise for the IV formulation 12 IV BCV: Fulfilling the Potential of Brincidofovir IV BCV delivers uniform exposure to key organs IV BCV delivers more drug to difficult-to-reach compartments, especially the brain IV BCV profile may allow for both treatment and prevention of DNA viral infection Does not over-expose gut which should allow for long-term tolerability Supports evaluation of IV BCV for viral brain infections, such as HHV6 encephalitis or JC virus Potential for once-weekly dosing and improved tolerability could allow for broader use in multiple viruses

13 IV BCV: Multiple-Ascending Dose Study Demonstrates Improved GI Tolerability  Multiple Ascending Dose (MAD) Study Design: – IV BCV 10 mg twice-weekly (BIW), 20 mg once-weekly (QW) for 4 doses – No dose-limiting clinical adverse events – No diarrhea with IV BCV 10 mg twice-weekly • IV BCV 10 mg provided plasma drug levels equivalent to oral BCV 100 mg which demonstrated antiviral activity in prior studies  Phase 2 IV BCV patient studies starting in 1H 2018 – Demonstrate PK and tolerability of multiple doses in adult HCT recipients – Evaluate relationship between dose and change-from-baseline in AdV in blood and stool – Data expected 2H 2018 to inform dose & dosing regimen for MVP-Peds study of multi- viral prevention

Multiviral Protection in Peds and Adult Allo-HCT BKV Treatment in Allo-HCT and SOT Other Uses of IV BCV in DNA Viral Infections 14 Building Full Potential Value for Oral and IV Brincidofovir – “Land and Expand” Pediatric & Adult Allo-HCT Recipients Treatment Pediatric & Adult Auto HCT and SOT Recipients Treatment Immunocompromised AdV Patients Treatment “Other” AdV Patients Treatment AdV EXPAND Via Lifecycle Management & Clinical Development LAND Pediatric & Adult Allo-HCT Recipients Prevention Pediatric & Adult Allo-HCT and SOT Recipients Treatment TBD

15 Anticipated Brincidofovir Milestones and Regulatory Decisions  Phase 2 IV BCV data to support dose-selection for MVP pivotal trial  IV BCV offers the promise of longer term dosing with improved tolerability 2017 2018 2022 MVP DATA 2019 2020 IV BCV for Multi-Viral Prevention IV BCV SAD IV BCV MAD IV BCV Ph 2 in adult HCT with AdV All timelines are estimated 2021 AdAPT DATA Oral BCV for AdV

16 Brincidofovir: Oral Antiviral With Demonstrated Activity Against Smallpox Oral BCV has demonstrated survival benefit in two animal models of fatal orthopoxvirus infections:  Rabbitpox virus model replicates human smallpox pathophysiology: asymptomatic infection, illness, and death – 100% survival demonstrated in animals that received immediate treatment with brincidofovir – Delayed treatment in 24 or 48 hrs resulted 93% survival  Mouse pox infection (ectromelia) replicates the respiratory infection route of human smallpox infection – Pivotal study to be conducted in 2018

Smallpox: Highest Bioweapon Threat 17 “The next epidemic could originate on the computer screen of a terrorist intent on using genetic engineering to create a synthetic version of the smallpox virus...” - Bill Gates, Munich, April 2017

UN Bioweapons Conference Confirms Global Concern  Chimerix sponsored a smallpox symposium in December 2017 at UN Biological Weapons Convention in Geneva – Threats from synthetic biology, undeclared smallpox stockpiles – Role of antivirals as medical countermeasures  Interest level exceeded expectations – Over 100 government agency attachés attended 18

19 Expedited EU Submission Supported for Brincidofovir  EMA marketing approval generally precedes procurement discussions in EU – Marketing Approval in EU can be cross-referenced for international procurement contracts outside the EU  Formal Scientific Advice was requested from the CHMP regarding required elements for a European marketing application for smallpox – Animal Efficacy Studies conducted for brincidofovir include a pivotal rabbitpox study which demonstrated 100% survival in animals treated at the time of confirmed infection compared with <50% survival in placebo animals (p<0.001) – Application would include data from over 50 studies in the supportive mousepox efficacy model  EMA responded that data from completed studies are sufficient for MAA submission: preparations are underway

20 Second Animal Model of Orthopoxvirus for US Submission 2017 2018 2019 2020 Oral BCV for smallpox Mouse Efficacy Study All timelines are estimated DATA Supportive Rabbit Study  Plan to initiate pivotal mouse study and supportive rabbit study in 2018  Data could support filing in US for smallpox in 2019

CMX521: The First Specific Antiviral for Norovirus  As a nucleoside selected from the Chimerix Chemical Library, CMX521: – targets the polymerase, an enzyme essential for viral replication – targets a portion of the virus that remains consistent across diverse strains – has demonstrated in vitro antiviral activity against all norovirus genotypes tested  First subject was dosed in December 2017, data anticipated in 2018 – Intestinal biopsies will determine intracellular drug levels for the target cells – Drug levels in intestinal cells that achieve effective in vitro concentrations could de-risk program  ~700 million cases of norovirus each year  Tremendous economic toll: >$60 billion/yr 21

22 Treatment Target is the Gut Epithelia Norovirus replicates in epithelium of the gut May need to target only cells represented by yellow highlight Without CMX521 CMX521 3 hrs before virus CMX521 at time of virus  In vitro, efficacious levels of active antiviral reached at 2-4 hours after drug exposure  Active antiviral half-life is 24 hours: suggests once-daily dosing CMX521 Decreases Norovirus >90% in vitro

Two Distinct Norovirus Opportunities  Treatment of Chronic Norovirus – Increasingly recognized in immunocompromised patients: • Stem cell transplant recipients • Solid organ transplant recipients • Other immunocompromised patients including those on biologics – Asymptomatic shedders who increase public health risks • Food handlers, healthcare workers  Prevention of Norovirus Outbreaks – At-risk individuals who have been exposed to a confirmed case of norovirus – Individuals who may be at risk due to a local outbreak without confirmed exposure – Individuals who elect to or need to be protected from a potential outbreak 23

24 CMRX: Building A Pipeline of Solutions for Patients at Risk of Serious Viral Infections 2017 2018 2021 MVP / pivotal DATA 2019 2020 IV BCV for Multi-Viral Prevention 2022 AdAPT DATA Oral BCV for AdV CMX521 SAD/MAD CMX521 POC CMX521 Treatment of Norovirus CMX521 Prevention of Norovirus Outbreaks DATA CMX521 for Norovirus Oral BCV for smallpox Mouse Efficacy Study DATA AdAPT Adult IV BCV Ph 2 in adult HCT with AdV

25 CMRX: Four Active Clinical Programs in 2018 Program Indication Pre-clinical Phase 1 Phase 2 Phase 3 Status Anticipated Approval Short-course Oral BCV AdV Treatment AdAPT enrolling 2021 Smallpox Animal Rule models progressing 2020 IV BCV Multi-viral Prevention Ph 2 in patients 2018 2022 CMX521 Norovirus SAD/MAD in 2018 2023  Chimerix remains well-capitalized with $241M at the end of 3Q 2017  Patent protection into 2034 for brincidofovir, and 2036 for CMX521